Chemical Biology Program
The Daniel Bachovchin Lab
Research in the Bachovchin lab focuses on characterizing the functions of enzymes in normal and pathological processes. In particular, we are interested in the roles that serine proteases play in cancer and immune system signaling. We use a variety of tools and approaches to study these enzymes and pathways, including new chemical probes developed in our lab, mass spectrometry-based proteomics, activity-based protein profiling, and genome engineering (CRISPR).
Chui, A.J*; Okondo, M.C.*; Rao, S.D.*; Gai, K.; Griswold, A.R.; Johnson, D.C.; Ball, D.P.; Taabazuing, C.Y.; Orth, E.L.; Vittimberga, B.A.; Bachovchin, D.A. # “N-terminal degradation activates the Nlrp1b inflammasome.” Science. 2019, 365, 82-85.
Griswold, A.R.; Cifani, P.; Rao, S.D.; Axelrod, A.J.; Miele, M.M.; Hendrickson, R.C.; Kensis, A.; Bachovchin, D.A. # “A chemical strategy for protease substrate profiling.” Cell Chem Biol. 2019, 26, 901-907.
Daniel Bachovchin, PhD
- Chemical biologist Daniel Bachovchin designs selective inhibitors to study enzymes and pathways in cancer and immune system signaling.
- PhD, The Scripps Research Institute
- Email Address
- Josie Robertson Investigator (2015-2020)
- Sloan Research Fellow in Chemistry (2018)
- Stand Up to Cancer 2017 Innovative Research Grant Recipient (2017-2020)
- Pew-Stewart Scholar for Cancer Research (2017-2021)
- Pershing Square Sohn Prize for Young Innovators in Cancer Research (2018)
- California Breast Cancer Research Program Fellowship (2011-2012)
- National Science Foundation Predoctoral Fellowship (2006-2007)
The Bachovchin Laboratory is open to graduate students from the Tri-Institutional Training Program in Chemical Biology, the Tri-Institutional MD-PhD Program, the Gerstner Sloan Kettering Graduate Program, and the Weill Cornell Medical College Graduate Program in Pharmacology.
Postdoctoral research positions are currently available in the Bachovchin Laboratory.
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Daniel Bachovchin discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.